These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 28746164)

  • 1. Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.
    Husnik MJ; Brown ER; Marzinke M; Livant E; Palanee-Phillips T; Hendrix CW; Matovu Kiweewa F; Nair G; Soto-Torres LE; Schwartz K; Hillier SL; Baeten JM;
    J Acquir Immune Defic Syndr; 2017 Nov; 76(3):330-337. PubMed ID: 28746164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
    Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
    Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
    Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualitative Perceptions of Dapivirine VR Adherence and Drug Level Feedback Following an Open-Label Extension Trial.
    Naidoo K; Mansoor LE; Katz AWK; Garcia M; Kemigisha D; Morar NS; Zimba CC; Chitukuta M; Reddy K; Soto-Torres L; Naidoo S; Montgomery ET
    J Acquir Immune Defic Syndr; 2021 Apr; 86(4):e90-e96. PubMed ID: 33278181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
    Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
    AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
    Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
    J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.
    Garcia M; Luecke E; Mayo AJ; Scheckter R; Ndase P; Kiweewa FM; Kemigisha D; Musara P; Mansoor LE; Singh N; Woeber K; Morar NS; Jeenarain N; Gaffoor Z; Gondwe DK; Makala Y; Fleurs L; Reddy K; Palanee-Phillips T; Baeten JM; van der Straten A; Soto-Torres L; Torjesen K
    BMC Public Health; 2021 Nov; 21(1):2041. PubMed ID: 34749675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
    Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
    Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring.
    Noguchi LM; Hoesley C; Kelly C; Scheckter R; Bunge K; Nel A; Marzinke MA; Hendrix CW; Dezzutti CS; Hillier SL; Bogen DL; Piper JM; Beigi RH
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30602513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
    Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
    AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
    Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
    AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
    Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
    Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
    AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
    Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
    J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
    Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
    AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of Women Enrolled into a Randomized Clinical Trial of Dapivirine Vaginal Ring for HIV-1 Prevention.
    Palanee-Phillips T; Schwartz K; Brown ER; Govender V; Mgodi N; Kiweewa FM; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Naidoo S; Pather A; Phillip J; Husnik MJ; van der Straten A; Soto-Torres L; Baeten J
    PLoS One; 2015; 10(6):e0128857. PubMed ID: 26061040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.